

●▶ **Incyte**

*(FDA, Approval)*

Incyte's OPZELURA is now the first topical JAK inhibitor approved by the FDA to treat atopic dermatitis in children ages 2 to 11

●▶ **Johnson and Johnson**

*(FDA, Approval)*

FDA approves SC induction of TREMFYA, the first IL-23 inhibitor with both SC and IV options for UC and CD

●▶ **Merck**

*(FDA, Approval)*

FDA approves KEYTRUDA QLEX, an SC formulation of pembrolizumab with hyaluronidase, for adults across most solid tumor indications

●▶ **KalVista Pharmaceuticals**

*(EMA, Approval)*

KalVista Pharmaceuticals' EKTERLY has been approved in the EU & Switzerland for acute hereditary angioedema attacks; first oral on-demand HAE therapy



●▶ **Ono Pharmaceutical**

*( EMA, Approval )*

Ono Pharmaceutical's ROMVIMZA (vimseltinib) has been approved by the EC for adult patients with symptomatic TGCT where surgery is not feasible or poses high risk

●▶ **Johnson and Johnson**

*( Positive, CHMP Opinion )*

Johnson & Johnson receives positive CHMP opinion for TREMFYA 400 mg SC induction in UC

●▶ **Merck**

*( Positive, CHMP Opinion )*

Merck's ENFLONIA recommended by CHMP for RSV prevention in newborns and infants; EC decision expected by the end of Q4 2025

●▶ **Merck**

*( Positive, CHMP Opinion )*

Merck's KEYTRUDA gets positive CHMP opinions for a subcutaneous form (KEYTRUDA SC) and a new LA-HNSCC indication, with EC decisions expected in Q4 2025



●► **Nuvation Bio** *( Japan, MHLW, Approval )*

Nuvation Bio's IBTROZI has been approved in Japan for ROS1+ advanced NSCLC; Nippon Kayaku to commercialize IBTROZI in Japan

●► **Immuto Scientific** *( Partnership )*

Immuto Scientific raised \$8M and partnered with Daiichi Sankyo to advance oncology and immunology using its AI surfaceomics platform

●► **VectorY Therapeutics** *( Partnership )*

VectorY Therapeutics has licensed Shape Therapeutics' SHP-DB1 AAV capsid to advance its vectorized antibody therapies for three targets

